The latest statistics show that 422 million people have diabetes worldwide, a drastic increase from 108 million in 1980.
Shirley, New York - On April 16, 2019, the global leading peptide supplier Creative Peptides announced to reorganize its diabetes-related peptides for researchers who are committed to exploring a cure for people with diabetes, a chronic disease that has made life miserable for a large proportion of the population.
The latest statistics show that 422 million people have diabetes worldwide, a drastic increase from 108 million in 1980. Diabetes mellitus can be generally classified into two main types: type 1 (or insulin-dependent) and type 2 (or non-insulin-dependent). Type 1 diabetes was caused by lack of production and secretion of insulin, probably as a result of destruction of the insulin producing pancreatic β-cells. Type 2 Diabetes, featuring insulin resistance and the body’s inability to secrete enough insulin, accounts for nearly 90% of diabetes cases.
“While insulin therapy remains the standard therapy for achieving and maintaining adequate glycemic control, especially in hospitalized patients with critical and noncritical illnesses, peptide-based diabetes treatment is leading a revolution in the treatment of diabetes due to their multi-functional properties,” says Dr. Robert Martinez, head of Creative Peptides’ synthesis businesses. “A good example is Glucagon Like Peptides (especially GLP-1), which can improve postprandial glycaemia without the hypoglycaemia and weight gain associated with aggressive insulin therapy. Moreover, it has the potential to reduce cardiovascular related morbidity.”
Till now, a couple of stable GLP-1 agonists such as liraglutide, albiglutide and dulaglutide have been approved by FDA as a new class of diabetic drugs. In addition, other peptides could also be applied in diabetes research, including: Amylins Fragments (IAPP), Chromogranin A/ Pancreastatin, Exendins Fragments, Insulin C-Peptides, Insulin-Like Growth Factors Fragments (IGF fragments), Glucagons and Glucagon Like Peptides (GLP-1 / GLP-2), Gastric Inhibitory Polypeptide and Fragments, etc.
To know more about the diabetes-related peptides at Creative Peptides, please visit: https://www.creative-peptides.com/research-areas/peptides-in-diabetes.html.
About Creative Peptides
As the most thriving pharmaceutical companies are actively involved in this booming field of diabetes research, it is very necessary, more than ever, to use high quality cGMP (current Good Manufacturing Practice) peptides. Creative Peptides is one of the primary suppliers of diabetes related peptides with a range of more than 100 peptides, from milligrams to kilograms, generic standard to cGMP standard. As a reliable partner for GMP grade peptides manufacture, we have served a great many of customers by providing high quality peptides (≥99%) for their projects.
